Acorda Therapeutics Inc. (ACOR)

http://www.acorda.com/

http://finance.yahoo.com/q/ks?s=ACOR

http://www.form4oracle.com/company?cik=0001008848&ticker=acor

Acorda Therapeutics, Inc., a biopharmaceutical company, engages in the identification, development, and commercialization of various therapies for the improvement of neurological functions in people with multiple sclerosis (MS), spinal cord injury, and other disorders of the central nervous system in the United States. It markets Zanaflex Capsules and Zanaflex tablets, a short-acting drug indicated for the management of spasticity. The company's lead product candidate is Fampridine-SR, which is in a Phase III development for the improvement of walking ability in patients with MS. Its preclinical programs comprise remyelination programs that include two distinct therapeutic approaches to stimulate repair of the damaged myelin sheath in MS, Glial Growth Factor 2, or GGF-2, and remyelinating antibodies; and Chondroitinase Program that develops second generation approaches to overcoming the proteoglycan matrix. Acorda Therapeutics sells its products through internal specialty sales force and contract pharmaceutical telesales organizations. The company was founded in 1995 and is based in Hawthorne, New York.